Abstract: The present invention relates to a pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for SIP receptor's subtypes S1PR1 and S1PR4, and more particularly, relates to a pharmaceutical composition containing as an active ingredient a sphingolipid compound acting as a functional antagonist for S1PR1 and S1PR4, does not cause cardiovascular side effects, and is effective in preventing or treating alopecia areata.

Abstract: The present disclosure relates to a wearable monitor device and methods and systems for using such a device. In certain embodiments, the wearable monitor records cardiac data from a mammal and extracts particular features of interest. These features are then transmitted and used to provide health-related information about the mammal.

Abstract: A plasma electrode module, an underwater plasma discharge device including the plasma electrode module, and a water treatment system are provided. The plasma electrode module includes a conductive substrate including a plurality of holes, a ceramic layer surrounding a portion of the outer surface of the conductive substrate, and a plasma electrode disposed in each of the plurality of holes, wherein the plasma electrode has a multilayer structure in which a cylindrical ground portion, a fixed portion, and a discharge portion are sequentially stacked, the ground portion is in contact with the conductive substrate and plasma is generated on the discharge portion, and each of the plurality of holes has a diameter in a range of 1 mm to 10 mm.

Abstract: A light emitting display device includes a light emitting diode including a first electrode and a second electrode to which a driving voltage is applied, a driving transistor, a second transistor receiving a data voltage and connected to a D node, a storage capacitor connected to the driving transistor and an N node, a hold capacitor connected to the D node and the N node, a third transistor connected to the D node and the driving transistor, a fourth transistor receiving a reference voltage and connected to the driving transistor, a fifth transistor connected to the driving transistor and the N node, a sixth transistor receiving a driving low voltage and connected to the driving transistor, a seventh transistor receiving an initialization voltage and connected the driving transistor, and an eighth transistor connected to the driving transistor and the first electrode of the light emitting diode.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for S1P receptor's subtypes S1PR1 and S1PR4, and more particularly, relates to a pharmaceutical composition containing as an active ingredient a sphingolipid compound acting as a functional antagonist for S1PR1 and S1PR4, does not cause cardiovascular side effects, and is effective in preventing or treating alopecia areata.

Abstract: A frame structure for a vehicle includes: an inner panel connected to a side member and defining an inner side of a rear part of the side member; an outer panel connected to a rear side of the side member and coupled to an outer side of the inner panel defining a closed cross-section together with the inner panel and defining an outer side of the rear part of the side member; an opening portion formed below the inner and outer panels partially opening the closed cross-section so that a front end of a rear suspension arm can be inserted into the opening portion; and a reinforcing member disposed in the opening portion defining the closed cross-section together with the outer panel and the inner panel and configured to close an internal space in the outer and inner panels.

Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: A display device includes four pixel arrays, a data driver, and a demultiplexer. The data driver is electrically connected to first and second data output lines. The demultiplexer electrically connects first and second data lines to the first data output line and electrically connects third and fourth data lines to the second data output line. The first to fourth pixel arrays are adjacent to the first to fourth data lines, respectively. Each of the first to fourth pixel arrays includes first and second color pixels. The first color pixels in the second pixel array are connected to the second data line, the second color pixels in the second pixel array are connected to the third data line, the second color pixels in the third pixel array are connected to the third data line, and the first color pixels in the third pixel array are connected to the second data line.

Abstract: A prelithiated negative electrode, and a secondary battery including a prelithiated electrode, including a negative electrode current collector; and a negative electrode active material layer present on at least one surface of the negative electrode current collector. The negative electrode active material layer includes high-capacity artificial graphite having no carbon coating. The negative electrode active material layer is prelithiated, and the content of lithium intercalated to the prelithiated negative electrode active material layer is 3% to 5% based on the lithium content intercalated when the negative electrode is charged to 100%.

Abstract: The present disclosure relates to a method for manufacturing a frozen block by mixing meat, salts, vegetables, and alpha starch.

Abstract: A complementary thin film transistor (TFT) includes a substrate and a first TFT and a second TFT disposed on the substrate, wherein a first conductive semiconductor layer of the first TFT and a second gate electrode layer of the second TFT are disposed in the same layer and include the same material.

Abstract: In various embodiments, an antenna array may comprise a dielectric; a first patch antenna disposed on a first region of the dielectric; a second patch antenna disposed on a second region of the dielectric; and a ground layer including a first sub-ground layer in contact with a lower portion of the first region of the dielectric, a third sub-ground layer in contact with a lower portion of the second region of the dielectric, and a second sub-ground layer spaced apart from a lower portion between the first region and the second region of the dielectric.

Abstract: In various examples, systems and methods are disclosed that preserve rich spatial information from an input resolution of a machine learning model to regress on lines in an input image. The machine learning model may be trained to predict, in deployment, distances for each pixel of the input image at an input resolution to a line pixel determined to correspond to a line in the input image. The machine learning model may further be trained to predict angles and label classes of the line. An embedding algorithm may be used to train the machine learning model to predict clusters of line pixels that each correspond to a respective line in the input image. In deployment, the predictions of the machine learning model may be used as an aid for understanding the surrounding environment—e.g., for updating a world model—in a variety of autonomous machine applications.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for S1PR1 and S1PR4 of S1P receptors, and more specifically, to a pharmaceutical composition including, as an active ingredient, a sphingolipid compound which does not cause cardiovascular side effects by acting as a functional antagonist for S1PR1 and S1PR4 and has an effect of preventing or treating inflammatory bowel disease.

Abstract: The present disclosure relates to a wearable device that includes a housing, battery terminal connector, conductive traces, and an insulator for recording signals. The device may include a housing enclosing a circuit board and a battery. The device may include two conductive traces electrically connected to terminals of the battery and an insulator separating the conductive traces. The battery terminal connector can present both the conductive traces to the outer surface for coupling to a circuit board. The device can assess the physiological signals to infer a likelihood of arrhythmia of a user.

Abstract: The present disclosure relates to a wearable device and systems/methods relating to the device. Certain embodiments may include two flexible wings and a bridge connecting the two wings. In some embodiments, the upper surface of the bridge can be non-adhesive and uncoupled to the flexible wing such that the flexible wing can be decoupled from the bridge when the adhesive is adhered to the surface of a user.

Abstract: The present disclosure relates to a wearable device with a bridge portion and systems/methods relating to the device. Preferred embodiments may include two flexible wings and a bridge connecting the two wings. In some embodiments, the upper surface of the bridge can be non-adhesive and uncoupled to the flexible wing such that the flexible wing can be decoupled from the bridge when the adhesive is adhered to the surface of a user. The bridge can be narrower in some portions, and extend around the housing of the monitor. The bridge can extend beneath the housing and bisect the two flexible wings.

Abstract: A reverse osmosis system for a seawater desalination system is provided.

Abstract: The present disclosure relates to a wearable monitor device and methods and systems for using such a device. In certain embodiments, the wearable monitor records cardiac data from a mammal and extracts particular features of interest. These features are then transmitted and used to provide health-related information about the mammal.

Abstract: The present disclosure relates to a wearable device that includes a housing, battery terminal connector, conductive traces, and an insulator for recording signals. The device may include a housing enclosing a circuit board and a battery. The device may include two conductive traces electrically connected to terminals of the battery and an insulator separating the conductive traces. The battery terminal connector can present both the conductive traces to the outer surface for coupling to a circuit board. The device can assess the physiological signals to infer a likelihood of arrhythmia of a user.